- Trial phase
- Approved
- Time to market
- Already on the market. First approved in the US in February 2019 and in the EU in September 2018.
- Why 3/10
- Cablivi is an already-approved, commercialized drug with no pending regulatory decision or pivotal readout in the next 12 months. The pediatric label expansion (the most recent binary catalyst) already occurred in December 2025/January 2026. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5, and Cablivi is a modest contributor (roughly EUR 249M in 2024 sales) within Sanofi's massive EUR 51B+ revenue base, further anchoring the score at the low end of that range.
Cablivi has no scheduled PDUFA dates, AdComms, or pivotal readouts in the next 12 months. The key binary event (pediatric label expansion) already passed in early 2026. Watch Sanofi's Q4 2026 earnings (late January 2027) for Cablivi's quarterly sales trajectory and any commentary on competitive dynamics from emerging aTTP therapies. The next major Sanofi rare-disease catalyst is the venglustat PDUFA for Gaucher disease type 3 on November 25, 2026, a separate drug.
Price Chart
Executive Summary
Cablivi (caplacizumab-yhdp) is a first-in-class nanobody therapy for acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting disorder. Originally FDA-approved in February 2019 for adults, Sanofi secured a pediatric label expansion in December 2025 (announced January 2026) covering patients 12 years and older. The drug generated approximately EUR 249 million in 2024 sales (about 9.7% growth), making it a modest but steadily growing contributor within Sanofi's much larger rare-disease portfolio. With no pending regulatory decisions or pivotal readouts, Cablivi is a mature, commercial-stage asset with limited near-term binary catalysts for the stock.
How It Works
Cablivi is a type of engineered antibody fragment (called a nanobody) that blocks von Willebrand factor, a protein in the blood that helps platelets stick together and form clots. In aTTP, abnormal clumps of von Willebrand factor cause dangerous small blood clots throughout the body. By blocking this protein, Cablivi helps prevent those clots from forming.
Trial Status
Cablivi was approved by the FDA on February 6, 2019 for adults with aTTP based on the pivotal Phase 3 HERCULES trial. The FDA expanded the label on December 23, 2025 (announced January 5, 2026) to include pediatric patients 12 years and older, supported by retrospective real-world data showing an 80% clinical remission rate in 30 children. The drug is also approved in the European Union (since September 2018). Additional real-world evidence continues to accumulate, including the Capla 1000+ project (Coppo et al. 2025).
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA dates, AdComms, or pivotal readouts for Cablivi in the next 12 months. The pediatric label expansion (December 2025/January 2026) was the most recent regulatory catalyst.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report